Live Q&A: Can Novo Answer Its Critics and Face Down Obesity-Drug Rivals?

The blockbuster success of Ozempic and Wegovy made Novo seem unstoppable — but now the Danish drugmaker faces a host of challenges. Bloomberg's Rachel Evans speaks with Damian Garde, Naomi Kresge and Sara Sjolin in a Live Q&A on Friday 5 September at 2 p.m. CET / 8 a.m. ET. Bloomberg digital subscribers and Terminal clients have the exclusive opportunity to ask our team questions in real-time. This conversation will be recorded and be made available to listen and share.